DV
Dividend Vision

LBRX — LB Pharmaceuticals Inc Common Stock

LB Pharmaceuticals Inc Common Stock (LBRX)

Total return is 176.2% over the past 0.9 years, 156.8 points ahead of SPY at 19.4%. Its deepest 1-year drawdown was 17.8%.

LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing neuropsychiatric therapies, with its lead product LB-102 in Phase 3 trials for acute schizophrenia and Phase 2 trials for bipolar I depression and other indications. The company does not currently distribute dividends. This security appeals primarily to investors with risk tolerance for early-stage drug development, as the company has not yet commercialized any products.

LBRX key facts

Asset type
Stock
Asset class
Equity
Inception date
09/11/2025
Last close
$47.77
Market cap
$886,108,544
Average volume
295300.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.36